

# impact factor molecular therapy

impact factor molecular therapy is a critical metric used to evaluate the influence and prestige of scientific journals in the field of molecular therapeutics. This measurement reflects the average number of citations received per paper published in a specific journal during a defined period, typically two years. Understanding the impact factor of journals specializing in molecular therapy is essential for researchers, clinicians, and institutions aiming to publish high-quality work or stay updated with cutting-edge advancements. This article explores the concept of impact factor molecular therapy, its significance, factors influencing it, and how it shapes the landscape of molecular therapeutic research and publication. Additionally, the discussion covers key journals, citation dynamics, and the broader implications of impact factors in academic and clinical settings.

- Understanding Impact Factor in Molecular Therapy
- Significance of Impact Factor in Molecular Therapeutics
- Factors Influencing Impact Factor in Molecular Therapy Journals
- Top Journals with High Impact Factors in Molecular Therapy
- Impact Factor and Its Role in Research and Clinical Practice

## Understanding Impact Factor in Molecular Therapy

The impact factor is a quantitative tool used to assess the relative importance of a journal within its field, including molecular therapy. It is calculated annually by dividing the number of citations in the current year to articles published in the previous two years by the total number of articles published

during those two years. This metric helps gauge how frequently research published in a journal is referenced by other researchers, reflecting its influence and reach.

In the context of molecular therapy, impact factors serve as a benchmark for the quality and relevance of scientific content related to gene therapy, nucleic acid-based treatments, and molecularly targeted interventions. Researchers and institutions often rely on these figures to decide where to publish their findings and to identify valuable sources of information.

## **Calculation Methodology**

The impact factor calculation involves two key components: citations and citable items. Citations include references made to articles published in the journal during the two preceding years, while citable items typically consist of original research articles and reviews. Non-citable content such as editorials or letters may be excluded. This method provides a snapshot of the journal's scholarly impact over a short timeframe, emphasizing recent research trends.

## **Limitations of Impact Factor**

While impact factor molecular therapy provides useful insights, it has limitations. It may not fully reflect the quality of individual articles, can be influenced by journal size and publication practices, and might vary significantly across disciplines. Additionally, the two-year citation window may not capture the long-term influence of groundbreaking research in molecular therapy, which sometimes gains recognition over extended periods.

## **Significance of Impact Factor in Molecular Therapeutics**

The impact factor holds substantial significance in molecular therapeutics as it helps researchers, funding bodies, and academic institutions assess the credibility and visibility of journals publishing in this domain. High-impact journals are often perceived as more prestigious, attracting cutting-edge research and fostering scientific advancement.

Furthermore, impact factor molecular therapy influences career progression, grant approvals, and institutional rankings. Researchers aiming to disseminate their findings widely prefer journals with higher impact factors to maximize the visibility and recognition of their work.

## **Influence on Research Quality and Trends**

Journals with high impact factors in molecular therapy tend to publish studies that are methodologically robust, innovative, and clinically relevant. The reputation associated with these journals encourages rigorous peer review and adherence to ethical publication standards, promoting overall research quality within the field.

## **Role in Academic and Clinical Decision-Making**

Clinicians and healthcare policymakers often consult high-impact molecular therapy journals to guide therapeutic strategies and decision-making. The impact factor serves as an indirect indicator of the reliability and significance of the research findings presented, aiding in evidence-based practice.

## **Factors Influencing Impact Factor in Molecular Therapy Journals**

Several elements contribute to the impact factor of molecular therapy journals, affecting their citation rates and scholarly reputation. Understanding these factors is crucial for evaluating the dynamics behind impact factor fluctuations and journal rankings.

### **Publication Frequency and Article Types**

Journals that publish frequently and include a diverse range of article types, such as original research, comprehensive reviews, and meta-analyses, tend to garner more citations. Reviews, in particular, often

attract higher citation counts, positively influencing the impact factor molecular therapy.

## **Research Field and Citation Culture**

The molecular therapy field encompasses various sub-disciplines with differing citation behaviors. For example, rapidly evolving areas like gene editing may see quicker citation turnarounds, whereas niche topics might accumulate citations more slowly. The citation culture within the molecular therapeutic community also affects impact factors.

## **Journal Visibility and Indexing**

Visibility through indexing in prominent databases such as PubMed, Scopus, and Web of Science significantly impacts citation rates. Journals with broader accessibility and strong online presence are more likely to be cited, boosting their impact factor molecular therapy.

## **Editorial Policies and Peer Review**

Strict editorial standards and rigorous peer review processes enhance the quality and credibility of published articles, attracting citations. Journals that emphasize novelty, scientific rigor, and clinical applicability often achieve higher impact factors.

## **Top Journals with High Impact Factors in Molecular Therapy**

Several journals in molecular therapy consistently achieve high impact factors, reflecting their leadership in publishing influential research. These journals cover a wide range of topics, including gene therapy, RNA therapeutics, and molecular pharmacology.

- **Molecular Therapy:** As a flagship journal, it focuses on the development and application of

molecular and cellular therapies, boasting a notable impact factor.

- **Gene Therapy:** This journal specializes in gene transfer technologies and clinical applications, maintaining a strong citation record.
- **Human Gene Therapy:** Known for publishing cutting-edge research in gene-based treatments, it consistently ranks high in impact metrics.
- **Journal of Molecular Medicine:** Covering translational research bridging molecular biology and clinical medicine, this journal has a significant impact factor.
- **Nature Reviews Drug Discovery:** Although broader in scope, it includes molecular therapeutic developments and often ranks among the top journals by impact factor.

## Evaluating Journal Selection for Publication

Researchers should consider impact factor alongside other criteria such as audience, scope, and publication speed when choosing a journal. High impact factor molecular therapy journals offer greater recognition but may have more competitive acceptance rates.

## Impact Factor and Its Role in Research and Clinical Practice

The impact factor molecular therapy influences not only academic publication but also the translation of research findings into clinical practice. It helps identify authoritative sources that inform therapeutic innovation and patient care.

## **Advancing Therapeutic Innovations**

High-impact journals disseminate breakthrough studies that drive the development of novel molecular therapies, including gene editing tools, RNA-based drugs, and targeted delivery systems. The visibility afforded by impact factors accelerates the adoption of new treatments.

## **Guiding Evidence-Based Medicine**

Clinicians rely on research published in reputable molecular therapy journals to guide treatment protocols, ensuring that interventions are based on reliable and validated scientific evidence. Impact factor serves as a proxy for the trustworthiness of these sources.

## **Influence on Funding and Policy Decisions**

Funding agencies and policymakers often use impact factor metrics when evaluating grant proposals and setting research priorities. Journals with high impact factors attract submissions from leading scientists, shaping the direction of molecular therapeutic research.

## **Best Practices to Maximize Impact in Molecular Therapy Research**

- Publish in journals with appropriate impact factors aligned to research scope.
- Focus on methodological rigor and innovation to increase citation potential.
- Engage in collaborative and interdisciplinary research to broaden impact.
- Promote published work through academic networks and conferences.
- Stay updated with emerging trends in molecular therapy to target relevant topics.

## **Frequently Asked Questions**

### **What is the impact factor of the journal Molecular Therapy?**

As of the latest Journal Citation Reports, the impact factor of Molecular Therapy is approximately 11.3, reflecting its influence in the field of gene and cell therapy research.

### **How is the impact factor of Molecular Therapy calculated?**

The impact factor of Molecular Therapy is calculated based on the average number of citations received in a particular year by articles published in the journal during the two preceding years.

### **Why is the impact factor important for Molecular Therapy?**

The impact factor is important for Molecular Therapy because it indicates the journal's prestige, the relevance of its published research, and helps authors decide where to submit their work.

### **Has the impact factor of Molecular Therapy increased recently?**

Yes, the impact factor of Molecular Therapy has generally increased over recent years, reflecting growing interest and advancements in molecular and gene therapy research.

### **How does Molecular Therapy's impact factor compare to other journals in gene therapy?**

Molecular Therapy's impact factor is among the highest in the field of gene and cell therapy, making it a leading journal compared to others focused on similar research areas.

### **Can the impact factor of Molecular Therapy affect funding and**

## collaboration opportunities?

Yes, publishing in a high-impact journal like Molecular Therapy can enhance researchers' visibility, positively influencing funding prospects and opportunities for collaboration.

## Where can I find the most up-to-date impact factor for Molecular Therapy?

The most up-to-date impact factor for Molecular Therapy can be found on the journal's official website, Clarivate Analytics' Journal Citation Reports, or academic databases that track journal metrics.

## Additional Resources

### 1. *Molecular Therapy: Principles and Practice*

This comprehensive book explores the foundational principles of molecular therapy, detailing various therapeutic strategies that target genetic and molecular mechanisms. It covers gene editing, RNA interference, and viral vector delivery systems, providing insights into both preclinical studies and clinical applications. Readers will gain an understanding of how molecular therapy is revolutionizing treatment for genetic disorders and cancers.

### 2. *Advances in Molecular Therapy for Genetic Diseases*

Focusing on recent breakthroughs, this title delves into molecular therapies designed to correct or compensate for genetic mutations. It highlights cutting-edge technologies such as CRISPR-Cas9, antisense oligonucleotides, and gene replacement therapies. The book also discusses challenges in delivery methods, immune responses, and regulatory considerations.

### 3. *Impact Factor and Trends in Molecular Therapy Journals*

Ideal for researchers and academics, this book analyzes the publication landscape of molecular therapy research through impact factor metrics. It offers a critical evaluation of leading journals, citation trends, and the influence of high-impact studies on the direction of the field. The text serves as a guide for selecting reputable sources and understanding research impact.

#### *4. Gene Therapy and Molecular Medicine: From Bench to Bedside*

This volume bridges basic molecular research and clinical applications, offering case studies on gene therapy protocols for inherited and acquired diseases. It emphasizes translational science, detailing how laboratory discoveries are transformed into effective treatments. Ethical considerations and future prospects in molecular medicine are also discussed.

#### *5. RNA-Based Molecular Therapeutics: Mechanisms and Applications*

Dedicated to RNA therapeutics, this book reviews mechanisms of action for siRNA, miRNA, and mRNA therapies. It explores delivery challenges, stability issues, and immune modulation strategies to enhance therapeutic efficacy. The text also covers recent clinical trials and approved RNA-based drugs.

#### *6. Viral Vectors in Molecular Therapy: Design and Application*

This text provides an in-depth look at viral vector technology used in molecular therapy, including adenoviruses, lentiviruses, and adeno-associated viruses. It discusses vector design, tropism, safety profiles, and manufacturing processes. The book is essential for understanding how viral vectors enable targeted gene delivery.

#### *7. Nanotechnology in Molecular Therapy: Innovations and Impact*

Exploring the intersection of nanotechnology and molecular therapy, this book highlights nanoparticle-based delivery systems that improve targeting and reduce side effects. It reviews materials such as liposomes, dendrimers, and polymeric nanoparticles. Case studies demonstrate the impact of nanotechnology on therapeutic outcomes.

#### *8. Clinical Trials in Molecular Therapy: Design, Ethics, and Outcomes*

This title outlines the critical aspects of designing and conducting clinical trials for molecular therapies. It covers regulatory frameworks, patient recruitment, endpoint selection, and ethical challenges specific to gene and molecular therapies. Insights into interpreting trial data and post-market surveillance are also provided.

#### *9. Emerging Molecular Therapies for Cancer: Impact and Future Directions*

Focusing on oncological applications, this book reviews novel molecular therapies targeting cancer at the genetic and epigenetic levels. It discusses immunotherapy, targeted gene editing, and combination approaches that enhance treatment efficacy. Perspectives on overcoming resistance and improving patient outcomes are emphasized.

## **Impact Factor Molecular Therapy**

Find other PDF articles:

<https://staging.devenscommunity.com/archive-library-007/Book?dataid=IgB96-7316&title=2-1-practice-a-algebra-1-answers.pdf>

**impact factor molecular therapy: Lentivirus: New Insights for the Healthcare Professional: 2011 Edition** , 2012-01-09 Lentivirus: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Lentivirus in a compact format. The editors have built Lentivirus: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Lentivirus in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Lentivirus: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: Embolism and Thrombosis—Advances in Research and Treatment: 2012 Edition** , 2012-12-26 Embolism and Thrombosis—Advances in Research and Treatment: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Embolism and Thrombosis. The editors have built Embolism and Thrombosis—Advances in Research and Treatment: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Embolism and Thrombosis in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Embolism and Thrombosis—Advances in Research and Treatment: 2012 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2012 Edition** , 2013-01-10 Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Molecular Pharmacology. The editors have built Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Molecular

Pharmacology in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2012 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: *Advances in Nanotechnology Research and Application: 2012 Edition*** , 2012-12-26 *Advances in Nanotechnology Research and Application / 2012 Edition* is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Nanotechnology. The editors have built *Advances in Nanotechnology Research and Application / 2012 Edition* on the vast information databases of ScholarlyNews.™ You can expect the information about Nanotechnology in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of *Advances in Nanotechnology Research and Application / 2012 Edition* has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: *Parkinson's Disease: New Insights for the Healthcare Professional: 2012 Edition*** , 2012-12-10 *Parkinson's Disease: New Insights for the Healthcare Professional: 2012 Edition* is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Parkinson Disease. The editors have built *Parkinson's Disease: New Insights for the Healthcare Professional: 2012 Edition* on the vast information databases of ScholarlyNews.™ You can expect the information about Parkinson Disease in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of *Parkinson's Disease: New Insights for the Healthcare Professional: 2012 Edition* has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: *Advances in Nucleocapsid Research and Application: 2012 Edition*** , 2012-12-26 *Advances in Nucleocapsid Research and Application / 2012 Edition* is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Nucleocapsid in a concise format. The editors have built *Advances in Nucleocapsid Research and Application / 2012 Edition* on the vast information databases of ScholarlyNews.™ You can expect the information about Nucleocapsid in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of *Advances in Nucleocapsid Research and Application / 2012 Edition* has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: *Advances in Active Immunotherapy Research and Application: 2012 Edition*** , 2012-12-26 *Advances in Active Immunotherapy Research and Application / 2012 Edition* is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Active Immunotherapy in a concise format. The editors have built

Advances in Active Immunotherapy Research and Application / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Active Immunotherapy in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Advances in Active Immunotherapy Research and Application / 2012 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: Hemophilia: New Insights for the Healthcare Professional: 2011 Edition** , 2012-01-09 Hemophilia: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Hemophilia in a concise format. The editors have built Hemophilia: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Hemophilia in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Hemophilia: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: Apoproteins—Advances in Research and Application: 2012 Edition** , 2012-12-26 Apoproteins—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Apoproteins. The editors have built Apoproteins—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Apoproteins in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Apoproteins—Advances in Research and Application: 2012 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: Antimicrobials—Advances in Research and Application: 2012 Edition** , 2012-12-26 Antimicrobials—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Antimicrobials. The editors have built Antimicrobials—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Antimicrobials in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Antimicrobials—Advances in Research and Application: 2012 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: Engineered immune cells in cancer immunotherapy (EICCI)** Cristina Maccalli, Axel Schambach, Francisco Martin, Cameron Turtle, 2023-02-28

**impact factor molecular therapy: Drugs: Advances in Research and Application: 2011 Edition** , 2012-01-09 Drugs: Advances in Research and Application: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Trials. The editors

have built *Drugs: Advances in Research and Application: 2011 Edition* on the vast information databases of ScholarlyNews.™ You can expect the information about Trials in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of *Drugs: Advances in Research and Application: 2011 Edition* has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy:** Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition, 2012-01-09 *Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition* is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Pharmacology, Pharmacy, Drug Research, and Drug Innovation. The editors have built *Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition* on the vast information databases of ScholarlyNews.™ You can expect the information about Pharmacology, Pharmacy, Drug Research, and Drug Innovation in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of *Issues in Pharmacology, Pharmacy, Drug Research, and Drug Innovation: 2011 Edition* has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: Macrophages—Advances in Research and Application: 2012 Edition**, 2012-12-26 *Macrophages—Advances in Research and Application: 2012 Edition* is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Macrophages. The editors have built *Macrophages—Advances in Research and Application: 2012 Edition* on the vast information databases of ScholarlyNews.™ You can expect the information about Macrophages in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of *Macrophages—Advances in Research and Application: 2012 Edition* has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy:** *Neurological Disease: New Insights for the Healthcare Professional: 2012 Edition*, 2012-12-10 *Neurological Disease: New Insights for the Healthcare Professional / 2012 Edition* is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Neurological Disease in a compact format. The editors have built *Neurological Disease: New Insights for the Healthcare Professional / 2012 Edition* on the vast information databases of ScholarlyNews.™ You can expect the information about Neurological Disease in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of *Neurological Disease: New Insights for the Healthcare Professional / 2012 Edition* has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy:** Biological Factors: Advances in Research and Application: 2011 Edition, 2012-01-09 *Biological Factors: Advances in Research and Application: 2011 Edition* is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information

about Biological Factors. The editors have built Biological Factors: Advances in Research and Application: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Biological Factors in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Biological Factors: Advances in Research and Application: 2011 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: Viruses—Advances in Research and Application: 2012 Edition** , 2012-12-26 Viruses—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Viruses. The editors have built Viruses—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Viruses in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Viruses—Advances in Research and Application: 2012 Edition has been produced by the world's leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at <http://www.ScholarlyEditions.com/>.

**impact factor molecular therapy: Diagnosis and Management in Parkinson's Disease** Colin R Martin, Victor R Preedy, 2020-08-13 Diagnosis and Management in Parkinson's Disease: The Neuroscience of Parkinson's, Volume 1 provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. It fills a much-needed gap as a one-stop synopsis of everything concerning the neurology and neuroscience related to Parkinson's disease, from chemicals and cells to individuals. The book is an invaluable resource for neuroscientists, neurologists, and anyone in the field. - Offers the most comprehensive coverage of a broad range of topics related to Parkinson's disease - Serves as a foundational collection for neuroscientists and neurologists on the biology of disease and brain dysfunction - Contains in each chapter an abstract, key facts, mini dictionary of terms, and summary points to aid in understanding - Features preclinical and clinical studies to help researchers map out key areas for research and further clinical recommendations - Serves as a one-stop source for everything you need to know about Parkinson's disease

**impact factor molecular therapy: The Neuroscience of Parkinson's Disease** Colin R Martin, Victor R Preedy, 2020-12-21 The Neuroscience of Parkinson's Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. The book also fills a much-needed gap as a one-stop synopsis of everything to do with the neurology and neuroscience related to Parkinson's disease—from chemicals and cells to individuals. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field. - Offers the most comprehensive coverage of a broad range of topics related to Parkinson's disease - Serves as a foundational collection for neuroscientists and neurologists on the biology of disease and brain dysfunction - Contains in each chapter an abstract, key facts, mini dictionary of terms, and summary points to aid in understanding - Features preclinical and clinical studies to help researchers map out key areas for research and further clinical recommendations - Serves as a one-stop source for everything you need to know about Parkinson's disease

**impact factor molecular therapy: Development of Gene Therapies** Avery McIntosh, Oleksandr Sverdlov, 2024-05-23 Cell and gene therapies have become the third major drug modality in pharmaceutical medicine of the 21st century after low molecular weight and antibody drugs. The gene therapy (GTx) field is rapidly advancing, and yet there are still fundamental scientific questions that remain to be answered. Development of GTx products poses unique challenges and opportunities for drug developers. However, there is lack of a systematic exposition of the GTx product development and the pivotal role of the biostatistician in this process. Development of Gene Therapies: Strategic, Scientific, and Regulatory, and Access Considerations attempts to summarize the current state-of-the-art strategic, scientific, statistical, and regulatory aspects of GTx development. Intended to provide an exposition to the GTx new product development through peer-reviewed papers written by subject matter experts in this emerging field, this book will be useful for researchers in gene therapy drug development, biostatisticians, regulators, patient advocates, graduate students, and the finance and business development community . Key Features: A collection of papers covering a wide spectrum of topics in gene therapies (GTx), written by leading subject matter experts. An exposition of the core principles of GTx product development, emerging business models, industry standards, best practices, and regulatory pathways. An exposition of statistical and innovative modeling tools for design and analysis of clinical trials of GTx. Insights into commercial models, access hurdles, and health economics of gene therapies. Case studies of successful GTx approvals from core team members that developed the first two FDA-approved AAV gene therapies: Luxturna and Zolgensma. A discussion of potential benefits and hurdles to be overcome for GTx in coming years from a multi-stakeholder perspective.

## Related to impact factor molecular therapy

“Genshin Impact” - Impact 3 Impact

SCI JCR SCI JCR Impact Factor

**effect, affect, impact** “” - effect, affect, impact 1. effect. To effect ( ) which is an effect ( ) The new rules will effect ( ), which is an

**Communications Earth & Environment** - Communications Earth & Environment Nature Geoscience Nature

**csgo rating rws kast** rating rating 0.9 KD 1

**Impact** - 2011 1

**2025 win11** - win11: win7 win7 win11 win10

**pc 200M** C 30.1G D 192G 290m C 30.4G

**10** - 10 research artical 10 IF 292 IF

**Nature synthesis** - Nature Synthesis JACS Nature Synthesis